My donor is incompatible, now what?

-
The best option for those with renal failure is a preemptive living donor kidney transplant. Unfortunately, many patients have family members or friends that wish to donate but preliminary testing reveals that they are either blood type or tissue type (HLA) incompatible.

In this situation, patients and their donors have two options:

  1. enter a donor exchange program to find a compatible donor. 
  2. undergo desensitization  to remove the incompatible antibodies 

    Donor exchanges

    There are two large nationwide donor exchange programs in the United States:

    1. OPTN kidney paired donation pilot program 
    2. National Kidney Registry (NKR) 
    Transplant Candidates that are receiving care at a U.S. transplant hospital, and are on the national organ transplant waiting list can join. They do not have to be on dialysis but must have a living donor who is willing to donate a kidney. The donor must be at least 18 years old and be willing to take part in a paired donation. 

    People who wish to donate a kidney to someone they don’t know are called non-directed, altruistic or Good Samaritan donors. These donors are encouraged to enter these exchanges to help start and continue transplant chains.





    Desensitization
    If a transplant is done in the setting of preformed antibodies, the graft will be lost to hyperacute rejection. Current strategies to remove antibodies have evolved over the last three decades and now achieve excellent results for ABO incompatible transplants.  Unfortunately,  these protocols have never been compared in clinical trials to determine the best approach. The general approach is to remove antibodies with plasmaphersis/ IVIG, and then keep them from being formed by using other drugs.

    The antibodies titers are reduced prior to transplantation to allow a compatible crossmatch. Additional immunosuppression is used after the transplant to keep the titers low until accommodation occurs. This typically takes two weeks. The therapies include plasmapheresis, IVIG, and rituximab. The cost of these transplants is higher and there is a higher risk of rejection and infection.  The additional cost depends on the protocol but it is still lower than the cost of chronic dialysis.

    The new kidney allocation system allows for donation of kidneys from an A2 deceased donor to blood type B recipients as long the the A2 titer is checked and falls below a certain threshold. This should reduce the waiting time for blood type B recipients. The recipient who's living donor has an A2 blood type may not require desensitization if the titer is low.

    Tissue type (HLA) incompatible transplants are more challenging. There are often many mismatched antigens. Multiple high level antibodies are difficult to eliminate and accommodation is less likely to occur. These patients are better served by donor exchange, especially if they are also ABO incompatible. Again desensitization is better than staying on chronic dialysis, especially if the waiting time for a deceased donor kidney is very long.







    Location: Des Moines, IA, USA

    Comments

    Post a Comment

    Popular posts from this blog

    Immunosuppression: why and how?

    -
    Image
    Background: Care is taken to perform compatible transplants by checking antibodies to blood (ABO) and tissue (HLA) antigens.The rejection of transplanted organs is caused by the activation of lymphocytes. HLA class 1 molecules are present on all nucleated cells and help the immune system to distinguish self from non-self.  HLA class 2 molecules are only present on antigen presenting cells (dendritic cells, monocytes, macrophages). The dendritic cells of the donor tissue migrate to the recipients lymphoid tissue and present them to the recipients lymphocytes, activating the overwhelming armamentarium of of the immune system. All blood cells arise from a common stem cell but the lymphocytes follow a different lineage.  Once activated, the T lymphocytes differentiate into cytotoxic T cells, tumor suppressor cells, and T-helper cells;  The B lymphocytes become plasma cells and memory cells.  There are essentially two types of rejection although a mixed pattern can be seen: 1
    Read more

    What is KDPI and does it matter?

    -
    Image
    The kidney donor profile index (KDPI)  is used in the new kidney allocation system to match the longevity of the kidney with that of the recipient to maximize the years of life gained through transplantation. It combines 10 donor factors into a single number that summarizes the potential risk of graft failure after kidney transplant.  It is not intended to serve as the only metric for determining donor suitability. Indeed the C-statistic for this is 0.6 , which is a little better than a coin toss. Many of the factors have no bearing on long-term function.  Pediatric en-bloc kidneys and dual kidneys from older donors will have very high KDPI even though they will work far better than a single adult kidney with KDPI<85. It is an improvement over the old system of standard criteria and extended criteria kidneys, but far from perfect.  Given the poor relationship to outcomes, I do not place much value on this in my practice. In my experience the factors that are more predi
    Read more

    I have a history of cancer, can I still get a transplant?

    -
    Image
    Patients on dialysis have an increased risk of cancer compared to the general population but there is no evidence to support more intensive screening of potential transplant recipients above that suggested for the general population. Cancer is responsible for 9–12% of deaths in renal transplant recipients. Post-transplant immunosuppression likely inhibits surveillance mechanisms that otherwise counteract the development of malignant cell growth. In fact, the risk of a developing new cancers exceeds the risk of recurrence of the original malignancy after transplantation.  Kidney failure patients that have been successfully treated for their cancer are generally considered to be suitable candidates for  transplantation. Tumor biology varies considerably between cancers and even within the same cancer, therefore a blanket recommendation for malignancy overall would not be valid. The current guidelines are based primarily on registry data from the Israel Penn International Transplant T
    Read more